Skip to main content
Equibles
MGX logo

MGX · Metagenomi Therapeutics, Inc.

Track MGX — free

Use MGX with AI

Ask our own analyst here, or connect this data to the AI you already use.

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

or use your own AI

The free Equibles MCP server lets any client query SEC filings, earnings calls, KPIs, holdings and prices directly — read-only, OAuth-secured, cited to the filing.

ChatGPT Claude Gemini
Server URL
https://mcp.equibles.com/mcp
All connection guides →
$1.17 +0.01 (+0.86%) At close · Sep 4
Rebalance outlook locked
Market Cap
$44.20M
Shares
37.78M

Price & Indicators

Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$1.17 Open$1.14 Day$1.14–1.17 52W close$1.14–3.35 Avg vol 30d133K Short int1.5M · 3.8% float · 11.0d Short vol18% Last earningsNov 12, 2025 DataFeb 2024–Sep 2026 Filing10-Q · Aug 10

Up next

Latest filing: 10-Q
filed Aug 10, 2026

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
$22.33M
Trailing 12 months
Net income (TTM)
−$93.46M
Trailing 12 months
Revenue growth YoY
-69.8%
Year over year
Operating margin
-380.9%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
-195.8%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$39.03M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+1.3%
Year over year · more shares
Price change (1Y)
-34.3%
Trailing year
Short interest
3.8%
Latest settlement · 11.0 days to cover
View all 114 metrics

Equibles Rating

blended score · not investment advice
Overall
Strong Sell
SellHoldBuy
Technical Sell Momentum Very Weak Sentiment Neutral Fundamentals Poor Quant / Vol Very High
Market backdrop VIX 14.5 · calm Equity put/call 0.58
Technical
price trend
Sell
50 / 200-day cross No cross
Price vs 200-day avg −18%
below
Price vs 50-day avg −5%
below
RSI (14) 40
neutral
MACD trend Negative
52-week position 1%
near low
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Very Weak
1-month return −5%
trailing
6-month return −21%
trailing
YTD return −28%
this year
Relative strength −36%
vs S&P · 6-mo
Sentiment
smart money
Neutral
Trend (MA cross) No cross
50d $1 › 200d $1 — 200d above 50d
Institutional flow Distributing
-10% holders QoQ · +4 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
3.85% of float · ▼ -2.7% MoM · 11.0 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr low
43 holders — near 2-yr low, contrarian setup
Squeeze score 58
elevated · 0–100
Fundamentals
Poor
Revenue growth −52%
Y/Y
EPS growth 0%
Y/Y
Free cash flow $-89.5M
Quant / Vol
risk profile
Very High
Volatility 63%
annualized · 1-yr
Max drawdown −66%
past year
ATR 3.6%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Sell
3 · 4 · 0
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
−18% Bearish
Price vs 50-day avg
−5% Neutral
RSI (14)
40 Neutral
MACD trend
Negative Bearish
52-week position
1% Bearish
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Mixed
Trend (MA cross) No cross
50d $1 › 200d $1 — 200d above 50d
Institutional flow Distributing
-10% holders QoQ · +4 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
3.85% of float · ▼ -2.7% MoM · 11.0 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr low
43 holders — near 2-yr low, contrarian setup
Price context
position in its 52-week range
Range low $1 Now $1 · 1% Range high $3
vs 200-day avg -18% vs 50-day avg -5%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
MGX
Metagenomi Therapeutics, Inc.
this stock
$44.20M -27.8% -51.8% — 3.8%
VRTX
Vertex Pharmaceuticals Inc / Ma
 $141.42B +20.5% +46.2% 32.5 1.6%
REGN
Regeneron Pharmaceuticals, Inc.
 $86.84B +7.2% +20.8% 20.9 2.3%
ARGX
Argenx SE
 $64.44B +22.9% — — 1.9%
CSLLY
Csl Ltd
 $60.55B — — — 0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Reducing
Holders
43
% held
16.6%
Net QoQ
-201.3K sh
Top holder
VANGUARD CAPITAL MANAGEME…
Held Float
View
Held by Funds
Fund positions
13
View
Short & Settlement
Short Interest Falling
Shares short
1.5M
Days to cover
11.0d
Change
-40.1K sh
View
Short Volume
Short vol %
18%
As of
Sep 4, 2026
Short Total
View
Fails to Deliver
FTD shares
6.7K
Value
$8.2K
As of
Aug 13, 2026
View
Off-Exchange
Off-exchange %
63.6%
Week of
Jul 27, 2026
Off-exch Lit
View
Financials
Financials
Revenue (FY)
$25.2M
Net income (FY)
$-87.9M
EPS diluted
$-2.36
View
Filings
SEC Filings
Latest
8-K
Filed
Aug 10, 2026
This year
9
View
Proposed Sales
Value
$68.1K
Shares
35.8K
Filed
Sep 11, 2025
View
Exempt Offerings
Offering
$100.0M
Filed
Jan 11, 2023
View
Earnings & Events
Earnings Calls
Last call
Nov 12, 2025
View

Performance

5D 20D 120D MTD YTD
MGX -1.7% -4.9% -21.0% -0.9% -27.8%
SPY +0.1% -0.4% +15.1% +0.4% +12.9%
vs SPY -1.8% -4.5% -36.1% -1.3% -40.7%
Key facts CIK 1785279 CUSIP 59102M104 13F (30d) 40 filings 39 filers Visit website Investor relations